SUBSCRIBERS
Sanofi to market new haemophilia drug in deal with Alnylam
Published Mon, Jan 8, 2018 · 09:50 PM
Paris
FRENCH pharmaceutical group Sanofi said it has obtained the right to develop and sell a new haemophilia drug in a restructuring of its partnership with Alnylam Pharmaceuticals.
Under the agreement, Sanofi will obtain global development and commercialisation rights to fitusiran, currently in development for the treatment of people with hemophilia A and B.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Holiday Inn owner IHG’s Q1 revenue up 2.6%, leisure travel demand remains strong
WSJ moves Asia headquarters from Hong Kong to Singapore
South Korea to slap fines on food suppliers for ‘shrinkflation’
Olam outbids Dreyfus’ sweetened deal for Australia’s Namoi, raises offer to A$0.66 per share
Live Nation’s revenue beats estimates as boom in concerts drive ticket sales
Jim Beam owner bets on canned vodka cocktails to double revenue